SCHEMBL27157330

SCHEMBL27157330

CC(C)(C)OC(=O)N1CCCC(C(=O)NNC(=O)c2ccccc2)C1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.62
▸ USP30 Q70CQ3 4/20 0.57
▸ KDM4E B2RXH2 4/20 0.56
▸ PKM P14618 1/20 0.56
▸ ALDH1A1 P00352 3/20 0.53
▸ HPGD P15428 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ ABL1 P00519 1/20 0.51
▸ RIN1 Q13671 1/20 0.51
▸ MEN1 O00255 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ ACKR3 P25106 1/20 0.48
▸ CYP2C19 P33261 1/20 0.47
▸ HPGDS O60760 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ STS P08842 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1651945 0.87 KMT2A (0.80) KMT2AKDM4EPKMALDH1A1ABL1
SCHEMBL27157338 0.85 KMT2A (0.50) KMT2AUSP30KDM4EPKMALDH1A1
SCHEMBL3325048 0.83 ALDH1A1 (0.58) KMT2AUSP30KDM4EPKMALDH1A1
SCHEMBL969043 0.83 ALDH1A1 (0.58) KMT2AUSP30KDM4EPKMALDH1A1
SCHEMBL969044 0.83 ALDH1A1 (0.58) KMT2AUSP30KDM4EPKMALDH1A1
SCHEMBL27157329 0.83 KMT2A (0.48) KMT2AUSP30KDM4EPKMALDH1A1
SCHEMBL29060740 0.83 KDM4E (0.63) KMT2AUSP30KDM4EPKMABL1
SCHEMBL5870918 0.83 ABL1 (0.62) KMT2AUSP30ALDH1A1HPGDRAB9A
SCHEMBL3715390 0.83 ABL1 (0.62) KMT2AUSP30ALDH1A1HPGDRAB9A
SCHEMBL30824540 0.82 USP30 (0.53) KMT2AUSP30KDM4ERAB9ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246952-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2024-07-25 — — US disclosed
CN-117751114-A Small molecule modulators of glucocerebrosidase activity and uses thereof 凡况生化公司 2024-03-22 — — CN disclosed
EP-4329880-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-03-06 — — EP disclosed
WO-2022232360-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246952-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF GBA1, GAA, GBA2 KMT2A 3498/4885USP30 2938/4885KDM4E 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback